Eris Lifesciences Limited has announced that a meeting of its Board of Directors will be held on Wednesday, May 20, 2026. The primary objective of this meeting is to review and approve the company’s standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. Additionally, the Board will consider the declaration of an interim dividend for the upcoming 2026-27 financial year.
Financial Results and Dividend Consideration
The leadership team at Eris Lifesciences is set to convene on May 20, 2026, to evaluate the company’s performance for the period ending March 31, 2026. This critical review will cover both standalone and consolidated audited financial results, providing stakeholders with a comprehensive view of the company’s fiscal health for the full year.
Shareholder Payout Discussion
Beyond the review of financial performance, the meeting will focus on capital allocation, specifically the potential declaration of an interim dividend for the 2026-27 financial year. Any decision regarding dividend payouts will be communicated following the conclusion of the board proceedings.
Trading Window Restrictions
The company has confirmed that the trading window for its designated persons and their immediate relatives has been closed since April 1, 2026. This restriction will remain in effect until 48 hours after the official declaration of the financial results to ensure market transparency and compliance with internal conduct policies.
Source: BSE
